Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US National institute of allergy and infectious disease has initiated a phase I/II study of Avant Immunotherapeutics' typhoid fever vaccine candidate, Ty800. The trial seeks to confirm the safety and immunogenicity of the vaccine observed in an earlier study.
Subscribe to our email newsletter
The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult volunteers and will follow each subject for six months post-vaccination.
Avant has designed the Ty800 vaccine to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S typhi.
“We are delighted that the NIAID is initiating clinical testing of our single-dose, oral Ty800 vaccine,” said Una Ryan, president and CEO of Avant. “The development of a safe and effective typhoid fever vaccine is important for protecting residents, travelers and military personnel from typhoid fever in endemic areas.”